New ADHD pill tested for Year-Long safety in kids

NCT ID NCT07087327

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the safety of an experimental drug called EB-1020, taken once daily, in 180 children and adolescents with ADHD over 52 weeks. Researchers will monitor side effects and how well participants tolerate the medication. The trial is open to those who completed a prior study or new participants diagnosed with ADHD.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT/HYPERACTIVITY DISORDER(ADHD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

Locations

  • Hokkaido University Hospital

    RECRUITING

    Sapporo, Japan